Limits...
High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers.

Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, Liu J, Liu D, Zhang S, Lin B - PLoS ONE (2013)

Bottom Line: The study cases included 34 cases of ovarian carcinoma with resistance to chemotherapeutic drugs, 6 partially drug-sensitive cases, and 52 drug-sensitive cases (92 total).The rates of expression of Lewis y antigen and CD44 antigen were significantly greater in the drug-resistant group than that in the partially-sensitive or sensitive groups.Surgical stage, residual tumor size and expression of CD44 and Lewis y antigen in ovarian carcinoma tissues were independent risk factors for chemotherapeutic drug resistance.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital/China Medical University, Shenyang, Liaoning Province, China.

ABSTRACT

Objectives: To measure Lewis y antigen and CD44 antigen expression in epithelial ovarian carcinoma and to correlate the levels of these antigens with clinical response to chemotherapy.

Methods: The study cases included 34 cases of ovarian carcinoma with resistance to chemotherapeutic drugs, 6 partially drug-sensitive cases, and 52 drug-sensitive cases (92 total).

Results: The rates of expression of Lewis y antigen and CD44 antigen were significantly greater in the drug-resistant group than that in the partially-sensitive or sensitive groups. Surgical stage, residual tumor size and expression of CD44 and Lewis y antigen in ovarian carcinoma tissues were independent risk factors for chemotherapeutic drug resistance.

Conclusions: Over-expression of Lewis y and CD44 antigen are strong risk factors for chemotherapeutic drug resistance in ovarian carcinoma patients.

Show MeSH

Related in: MedlinePlus

The expression of CD44 antigen in ovarian carcinoma tissues, CD44 primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (A chemotherapy-resistant group; B chemotherapy-sensitive group. ×200).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585297&req=5

pone-0057250-g002: The expression of CD44 antigen in ovarian carcinoma tissues, CD44 primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (A chemotherapy-resistant group; B chemotherapy-sensitive group. ×200).

Mentions: CD44 was also primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (Figure 2). The rates of positive expression of CD44 in the drug-resistant, partially sensitive and sensitive groups were 91.17%, 66.67% and 51.92%, respectively (Table 1). The rate of expression of CD44 in the drug-resistant group was significantly higher than that in the sensitive group (0.01<p<0.05), but no significant difference was observed between the drug-resistant group and the partially sensitive group (p = 0.154).


High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers.

Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, Liu J, Liu D, Zhang S, Lin B - PLoS ONE (2013)

The expression of CD44 antigen in ovarian carcinoma tissues, CD44 primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (A chemotherapy-resistant group; B chemotherapy-sensitive group. ×200).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585297&req=5

pone-0057250-g002: The expression of CD44 antigen in ovarian carcinoma tissues, CD44 primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (A chemotherapy-resistant group; B chemotherapy-sensitive group. ×200).
Mentions: CD44 was also primarily localized to the cell membrane, but was also observed in the cytoplasm and in the interstitial spaces outside of tumor cells (Figure 2). The rates of positive expression of CD44 in the drug-resistant, partially sensitive and sensitive groups were 91.17%, 66.67% and 51.92%, respectively (Table 1). The rate of expression of CD44 in the drug-resistant group was significantly higher than that in the sensitive group (0.01<p<0.05), but no significant difference was observed between the drug-resistant group and the partially sensitive group (p = 0.154).

Bottom Line: The study cases included 34 cases of ovarian carcinoma with resistance to chemotherapeutic drugs, 6 partially drug-sensitive cases, and 52 drug-sensitive cases (92 total).The rates of expression of Lewis y antigen and CD44 antigen were significantly greater in the drug-resistant group than that in the partially-sensitive or sensitive groups.Surgical stage, residual tumor size and expression of CD44 and Lewis y antigen in ovarian carcinoma tissues were independent risk factors for chemotherapeutic drug resistance.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital/China Medical University, Shenyang, Liaoning Province, China.

ABSTRACT

Objectives: To measure Lewis y antigen and CD44 antigen expression in epithelial ovarian carcinoma and to correlate the levels of these antigens with clinical response to chemotherapy.

Methods: The study cases included 34 cases of ovarian carcinoma with resistance to chemotherapeutic drugs, 6 partially drug-sensitive cases, and 52 drug-sensitive cases (92 total).

Results: The rates of expression of Lewis y antigen and CD44 antigen were significantly greater in the drug-resistant group than that in the partially-sensitive or sensitive groups. Surgical stage, residual tumor size and expression of CD44 and Lewis y antigen in ovarian carcinoma tissues were independent risk factors for chemotherapeutic drug resistance.

Conclusions: Over-expression of Lewis y and CD44 antigen are strong risk factors for chemotherapeutic drug resistance in ovarian carcinoma patients.

Show MeSH
Related in: MedlinePlus